Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir amibufenamide fumarate
- Development stage
- Unknown
- Lead developer
- Hansoh Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tenofovir amibufenamide fumarate (TMF) is a novel, orally active nucleotide reverse transcriptase inhibitor (NRTI) and a second-generation prodrug of tenofovir. Developed by Hansoh Pharma, it was approved in China in June 2021 for the treatment of chronic hepatitis B virus (HBV) infection in adults. TMF is designed using ProTide technology, featuring an additional methyl group compared to tenofovir alafenamide (TAF), which enhances its plasma stability, lipid solubility, and cell membrane penetration. This optimization allows for efficient delivery of the active metabolite, tenofovir diphosphate, directly to hepatocytes, resulting in potent antiviral efficacy at a lower dose (25 mg daily) with reduced systemic exposure and improved bone and renal safety compared to tenofovir disoproxil fumarate (TDF).
- Brand names
- Heng muHengmu
- Other names
- tenofovir amibufenamideTMF
02
Targets
HBV Pol (Hepatitis B virus polymerase)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on tenofovir amibufenamide fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir amibufenamide fumarate.